

Karen E Knudsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3018657/publications.pdf>

Version: 2024-02-01

157
papers

15,919
citations

13854

67
h-index

17580

121
g-index

160
all docs

160
docs citations

160
times ranked

21086
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1697-1708.	13.9	1,796
2	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. <i>Cell</i> , 2018, 174, 758-769.e9.	13.5	459
3	Prostate cancer. <i>Nature Reviews Disease Primers</i> , 2021, 7, 9.	18.1	434
4	Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1106-15.	3.3	376
5	Dual Roles of PARP-1 Promote Cancer Growth and Progression. <i>Cancer Discovery</i> , 2012, 2, 1134-1149.	7.7	354
6	Tailoring to RB: tumour suppressor status and therapeutic response. <i>Nature Reviews Cancer</i> , 2008, 8, 714-724.	12.8	311
7	AR, the cell cycle, and prostate cancer. <i>Nuclear Receptor Signaling</i> , 2008, 6, nrs.06001.	1.0	300
8	A Hormone-Dependent DNA Repair Circuit Governs the Response to Genotoxic Insult. <i>Cancer Discovery</i> , 2013, 3, 1254-1271.	7.7	294
9	Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 4792-4798.	3.2	275
10	The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. <i>Journal of Clinical Investigation</i> , 2010, 120, 4478-4492.	3.9	268
11	Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. <i>Endocrine-Related Cancer</i> , 2011, 18, 333-345.	1.6	256
12	An evaluation of evidence for the carcinogenic activity of bisphenol A. <i>Reproductive Toxicology</i> , 2007, 24, 240-252.	1.3	249
13	Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. <i>Trends in Endocrinology and Metabolism</i> , 2010, 21, 315-324.	3.1	248
14	The meaning of p16 ^{ink4a} expression in tumors. <i>Cell Cycle</i> , 2011, 10, 2497-2503.	1.3	240
15	PCAT-1, a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer. <i>Cancer Research</i> , 2014, 74, 1651-1660.	0.4	237
16	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. <i>Cancer Discovery</i> , 2017, 7, 999-1005.	7.7	223
17	The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc. <i>Neoplasia</i> , 2014, 16, 900-908.	2.3	216
18	RB-Dependent S-Phase Response to DNA Damage. <i>Molecular and Cellular Biology</i> , 2000, 20, 7751-7763.	1.1	213

#	ARTICLE	IF	CITATIONS
19	Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors. <i>Neoplasia</i> , 2015, 17, 385-399.	2.3	212
20	Beyond DNA Repair: DNA-PK Function in Cancer. <i>Cancer Discovery</i> , 2014, 4, 1126-1139.	7.7	202
21	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. <i>Clinical Cancer Research</i> , 2019, 25, 6916-6924.	3.2	200
22	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020, 52, 778-789.	9.4	198
23	The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. <i>Journal of Clinical Investigation</i> , 2007, 117, 218-228.	3.9	178
24	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. <i>Journal of Clinical Oncology</i> , 2020, 38, 2798-2811.	0.8	170
25	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. <i>Journal of Clinical Oncology</i> , 2018, 36, 991-999.	0.8	169
26	Multiple G1 Regulatory Elements Control the Androgen-dependent Proliferation of Prostatic Carcinoma Cells. <i>Journal of Biological Chemistry</i> , 1998, 273, 20213-20222.	1.6	165
27	RB-pathway disruption in breast cancer. <i>Cell Cycle</i> , 2010, 9, 4153-4163.	1.3	163
28	FOXA1: master of steroid receptor function in cancer. <i>EMBO Journal</i> , 2011, 30, 3885-3894.	3.5	162
29	Alternative Splicing of the Cyclin D1 Proto-Oncogene Is Regulated by the RNA-Binding Protein Sam68. <i>Cancer Research</i> , 2010, 70, 229-239.	0.4	157
30	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018, 36, 414-424.	0.8	155
31	Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 1038-1046.	0.4	149
32	DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. <i>Cancer Cell</i> , 2015, 28, 97-113.	7.7	148
33	Transcriptional Roles of PARP1 in Cancer. <i>Molecular Cancer Research</i> , 2014, 12, 1069-1080.	1.5	144
34	Cancer and the Circadian Clock. <i>Cancer Research</i> , 2019, 79, 3806-3814.	0.4	140
35	The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 515-24.	1.9	130
36	Cyclin D1: Mechanism and Consequence of Androgen Receptor Co-repressor Activity. <i>Journal of Biological Chemistry</i> , 2002, 277, 2207-2215.	1.6	128

#	ARTICLE	IF	CITATIONS
37	Targeting the p300/CBP Axis in Lethal Prostate Cancer. <i>Cancer Discovery</i> , 2021, 11, 1118-1137.	7.7	124
38	Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 2190-2195.	3.3	123
39	BAF57 Governs Androgen Receptor Action and Androgen-Dependent Proliferation through SWI/SNF. <i>Molecular and Cellular Biology</i> , 2005, 25, 2200-2215.	1.1	117
40	Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. <i>Molecular Cell</i> , 2015, 58, 925-934.	4.5	114
41	Ex vivo culture of human prostate tissue and drug development. <i>Nature Reviews Urology</i> , 2013, 10, 483-487.	1.9	111
42	Hus1p, a conserved fission yeast checkpoint protein, interacts with Rad1p and is phosphorylated in response to DNA damage. <i>EMBO Journal</i> , 1998, 17, 2055-2066.	3.5	110
43	Hijacking the Chromatin Remodeling Machinery: Impact of SWI/SNF Perturbations in Cancer. <i>Cancer Research</i> , 2009, 69, 8223-8230.	0.4	102
44	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. <i>Cell Reports</i> , 2017, 19, 2045-2059.	2.9	99
45	Targeting cell cycle and hormone receptor pathways in cancer. <i>Oncogene</i> , 2013, 32, 5481-5491.	2.6	98
46	USP22 Regulates Oncogenic Signaling Pathways to Drive Lethal Cancer Progression. <i>Cancer Research</i> , 2014, 74, 272-286.	0.4	98
47	Compensation of BRG-1 Function by Brm. <i>Journal of Biological Chemistry</i> , 2002, 277, 4782-4789.	1.6	97
48	Molecular Pathogenesis and Progression of Prostate Cancer. <i>Seminars in Oncology</i> , 2013, 40, 244-258.	0.8	96
49	Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. <i>Cell</i> , 2018, 174, 1200-1215.e20.	13.5	96
50	A patient-derived explant (PDE) model of hormone-dependent cancer. <i>Molecular Oncology</i> , 2018, 12, 1608-1622.	2.1	94
51	Differential Requirement of SWI/SNF for Androgen Receptor Activity. <i>Journal of Biological Chemistry</i> , 2003, 278, 30605-30613.	1.6	93
52	Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 3562-3570.	3.2	92
53	Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E9298-E9307.	3.3	91
54	Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 795-807.	3.2	89

#	ARTICLE	IF	CITATIONS
55	2,3,7,8-Tetrachlorodibenzo-p-dioxin Blocks Androgen-Dependent Cell Proliferation of LNCaP Cells through Modulation of pRB Phosphorylation. <i>Molecular Pharmacology</i> , 2004, 66, 502-511.	1.0	85
56	Retinoblastoma Tumor Suppressor: Where Cancer Meets the Cell Cycle. <i>Experimental Biology and Medicine</i> , 2006, 231, 1271-1281.	1.1	85
57	Cyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 5338-5349.	3.2	84
58	Differential impact of RB status on E2F1 reprogramming in human cancer. <i>Journal of Clinical Investigation</i> , 2017, 128, 341-358.	3.9	83
59	Retinoblastoma Tumor Suppressor Status Is a Critical Determinant of Therapeutic Response in Prostate Cancer Cells. <i>Cancer Research</i> , 2007, 67, 6192-6203.	0.4	77
60	MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4201-4214.	3.2	77
61	The Epigenetic Modifier Ubiquitin-specific Protease 22 (USP22) Regulates Embryonic Stem Cell Differentiation via Transcriptional Repression of Sex-determining Region Y-box 2 (SOX2). <i>Journal of Biological Chemistry</i> , 2013, 288, 24234-24246.	1.6	74
62	AR function in promoting metastatic prostate cancer. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 399-411.	2.7	73
63	Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 3181-3190.	1.9	72
64	The SWI/SNF ATPase Brm Is a Gatekeeper of Proliferative Control in Prostate Cancer. <i>Cancer Research</i> , 2008, 68, 10154-10162.	0.4	71
65	Targeting the BAF57 SWI/SNF Subunit in Prostate Cancer: A Novel Platform to Control Androgen Receptor Activity. <i>Cancer Research</i> , 2008, 68, 4551-4558.	0.4	71
66	Identification of ASF/SF2 as a Critical, Allele-Specific Effector of the Cyclin D1b Oncogene. <i>Cancer Research</i> , 2010, 70, 3975-3984.	0.4	71
67	Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. <i>Prostate</i> , 2019, 79, 333-339.	1.2	69
68	Detection of Activating Estrogen Receptor Gene (<i>ESR1</i>) Mutations in Single Circulating Tumor Cells. <i>Clinical Cancer Research</i> , 2017, 23, 6086-6093.	3.2	68
69	Androgen receptor corepressors and prostate cancer. <i>Endocrine-Related Cancer</i> , 2006, 13, 979-994.	1.6	67
70	RB Loss Promotes Prostate Cancer Metastasis. <i>Cancer Research</i> , 2017, 77, 982-995.	0.4	67
71	Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. <i>Cancer Research</i> , 2005, 65, 54-65.	0.4	67
72	Cyclin A Is a Functional Target of Retinoblastoma Tumor Suppressor Protein-mediated Cell Cycle Arrest. <i>Journal of Biological Chemistry</i> , 1999, 274, 27632-27641.	1.6	66

#	ARTICLE	IF	CITATIONS
73	Cyclin D1b Is Aberrantly Regulated in Response to Therapeutic Challenge and Promotes Resistance to Estrogen Antagonists. <i>Cancer Research</i> , 2008, 68, 5628-5638.	0.4	65
74	A central domain of cyclin D1 mediates nuclear receptor corepressor activity. <i>Oncogene</i> , 2005, 24, 431-444.	2.6	63
75	Specificity of cyclin D1 for androgen receptor regulation. <i>Cancer Research</i> , 2003, 63, 4903-13.	0.4	63
76	The cyclin D1b splice variant: an old oncogene learns new tricks. <i>Cell Division</i> , 2006, 1, 15.	1.1	62
77	The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair. <i>Nature Communications</i> , 2021, 12, 401.	5.8	60
78	Posttranscriptional Regulation of <i>PARG</i> mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors. <i>Cancer Research</i> , 2017, 77, 5011-5025.	0.4	59
79	Cellular rewiring in lethal prostate cancer: the architect of drug resistance. <i>Nature Reviews Urology</i> , 2020, 17, 292-307.	1.9	59
80	The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. <i>Oncogene</i> , 1999, 18, 5239-5245.	2.6	57
81	Nuclear Targeting of Cyclin-Dependent Kinase 2 Reveals Essential Roles of Cyclin-Dependent Kinase 2 Localization and Cyclin E in Vitamin D-Mediated Growth Inhibition. <i>Endocrinology</i> , 2010, 151, 896-908.	1.4	54
82	Retinoblastoma Tumor Suppressor Protein Signals through Inhibition of Cyclin-Dependent Kinase 2 Activity To Disrupt PCNA Function in S Phase. <i>Molecular and Cellular Biology</i> , 2001, 21, 4032-4045.	1.1	53
83	Linking DNA Damage and Hormone Signaling Pathways in Cancer. <i>Trends in Endocrinology and Metabolism</i> , 2016, 27, 216-225.	3.1	52
84	PARP α 1 regulates DNA repair factor availability. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	52
85	PARP Inhibitors in Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 37.	1.3	50
86	Targeted Radiosensitization of ETS Fusion-Positive Prostate Cancer through PARP1 Inhibition. <i>Neoplasia</i> , 2013, 15, 1207-IN36.	2.3	49
87	Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. <i>Expert Review of Endocrinology and Metabolism</i> , 2011, 6, 483-493.	1.2	48
88	mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. <i>Endocrine-Related Cancer</i> , 2012, 19, 1-12.	1.6	48
89	Targeting PARP-1 Allosteric Regulation Offers Therapeutic Potential against Cancer. <i>Cancer Research</i> , 2014, 74, 31-37.	0.4	47
90	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 471.	3.4	46

#	ARTICLE	IF	CITATIONS
91	USP22 Functions as an Oncogenic Driver in Prostate Cancer by Regulating Cell Proliferation and DNA Repair. <i>Cancer Research</i> , 2020, 80, 430-443.	0.4	46
92	The AR dependent cell cycle: Mechanisms and cancer relevance. <i>Molecular and Cellular Endocrinology</i> , 2012, 352, 34-45.	1.6	45
93	Models of neuroendocrine prostate cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, R33-R49.	1.6	45
94	RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 687-697.	3.2	43
95	Optimizing the Use of Telemedicine in Oncology Care: Postpandemic Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 933-936.	3.2	42
96	Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression. <i>Molecular Cancer Research</i> , 2015, 13, 1591-1601.	1.5	41
97	DNA Damage Response in Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a030486.	2.9	40
98	RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease. <i>Cancer Discovery</i> , 2021, 11, 2334-2353.	7.7	40
99	Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. <i>Nature Reviews Urology</i> , 2011, 8, 562-568.	1.9	39
100	Functional Specificities of Brm and Brg-1 Swi/Snf ATPases in the Feedback Regulation of Hepatic Bile Acid Biosynthesis. <i>Molecular and Cellular Biology</i> , 2009, 29, 6170-6181.	1.1	38
101	Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. <i>Clinical Cancer Research</i> , 2019, 25, 4290-4299.	3.2	38
102	Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. <i>Journal of Clinical Investigation</i> , 2013, 123, 493-508.	3.9	38
103	Cyclin D1 Is a Selective Modifier of Androgen-dependent Signaling and Androgen Receptor Function*. <i>Journal of Biological Chemistry</i> , 2011, 286, 8117-8127.	1.6	37
104	Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. <i>European Urology Oncology</i> , 2018, 1, 325-337.	2.6	37
105	Unique Bisphenol A Transcriptome in Prostate Cancer: Novel Effects on ER β Expression That Correspond to Androgen Receptor Mutation Status. <i>Environmental Health Perspectives</i> , 2007, 115, 1646-1653.	2.8	36
106	Progesterone Receptor α -Cyclin D1 Complexes Induce Cell Cycle α -Dependent Transcriptional Programs in Breast Cancer Cells. <i>Molecular Endocrinology</i> , 2014, 28, 442-457.	3.7	36
107	Targeting Pioneering Factor and Hormone Receptor Cooperative Pathways to Suppress Tumor Progression. <i>Cancer Research</i> , 2012, 72, 1248-1259.	0.4	35
108	Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non α -Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1402-1414.	3.2	34

#	ARTICLE	IF	CITATIONS
109	The Complex Role of AR Signaling After Cytotoxic Insult: Implications for Cell Cycle Based Chemotherapeutics. <i>Cell Cycle</i> , 2007, 6, 1307-1313.	1.3	32
110	Aberrant BAF57 Signaling Facilitates Prometastatic Phenotypes. <i>Clinical Cancer Research</i> , 2013, 19, 2657-2667.	3.2	32
111	Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 2439-2452.	0.4	32
112	Cell cycle-coupled expansion of AR activity promotes cancer progression. <i>Oncogene</i> , 2017, 36, 1655-1668.	2.6	32
113	SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. <i>Science Advances</i> , 2019, 5, eaax6352.	4.7	31
114	Cell-cycle-dependent regulation of androgen receptor function. <i>Endocrine-Related Cancer</i> , 2015, 22, 249-264.	1.6	30
115	Decreased local immune response and retained HPV gene expression during chemoradiotherapy are associated with treatment resistance and death from cervical cancer. <i>International Journal of Cancer</i> , 2020, 146, 2047-2058.	2.3	26
116	Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies. <i>Clinical Cancer Research</i> , 2019, 25, 5623-5637.	3.2	23
117	Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer. <i>Oncogene</i> , 2009, 28, 1016-1027.	2.6	22
118	Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas <i>In Vivo</i> and <i>Ex Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2018, 17, 84-95.	1.9	22
119	Mitogenic Action of the Androgen Receptor Sensitizes Prostate Cancer Cells to Taxane-Based Cytotoxic Insult. <i>Cancer Research</i> , 2006, 66, 11998-12008.	0.4	21
120	DNA-PKcs: A Targetable Protumorigenic Protein Kinase. <i>Cancer Research</i> , 2022, 82, 523-533.	0.4	21
121	The Retinoblastoma Tumor Suppressor Modulates DNA Repair and Radioresponsiveness. <i>Clinical Cancer Research</i> , 2014, 20, 5468-5482.	3.2	19
122	Consequence of the tumor-associated conversion to cyclin D1b. <i>EMBO Molecular Medicine</i> , 2015, 7, 628-647.	3.3	19
123	A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3017-3027.	3.2	19
124	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. <i>Clinical Cancer Research</i> , 2019, 25, 5608-5622.	3.2	17
125	Caveolin-1 overexpression enhances androgen-dependent growth and proliferation in the mouse prostate. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 1318-1329.	1.2	16
126	Differential expression of $\alpha 2\beta 3$ and $\alpha 2\beta 6$ integrins in prostate cancer progression. <i>PLoS ONE</i> , 2021, 16, e0244985.	1.1	16

#	ARTICLE	IF	CITATIONS
127	The Role of Tumor Suppressor Dysregulation in Prostate Cancer Progression. <i>Current Drug Targets</i> , 2013, 14, 460-471.	1.0	16
128	Relevance of pRB Loss in Human Malignancies. <i>Clinical Cancer Research</i> , 2022, 28, 255-264.	3.2	15
129	2,2-Bis(4-Chlorophenyl)-1,1-Dichloroethylene Stimulates Androgen Independence in Prostate Cancer Cells through Combinatorial Activation of Mutant Androgen Receptor and Mitogen-Activated Protein Kinase Pathways. <i>Molecular Cancer Research</i> , 2008, 6, 1507-1520.	1.5	14
130	An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. <i>International Journal of Cancer</i> , 2019, 144, 1151-1159.	2.3	13
131	Mutant p53 elicits context-dependent pro-tumorigenic phenotypes. <i>Oncogene</i> , 2022, 41, 444-458.	2.6	13
132	Postprostatectomy radiation therapy: an evidence-based review. <i>Future Oncology</i> , 2011, 7, 1429-1440.	1.1	12
133	A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1446-1459.	3.2	12
134	The SAGA complex regulates early steps in transcription via its deubiquitylase module subunit USP22. <i>EMBO Journal</i> , 2021, 40, e102509.	3.5	9
135	Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle. <i>Cancer Cell</i> , 2017, 31, 471-473.	7.7	8
136	Assessing the Coverage of US Cancer Center Primary Catchment Areas. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 955-964.	1.1	8
137	Cyclin D1 goes metabolic. <i>Cell Cycle</i> , 2012, 11, 3534-3534.	1.3	6
138	Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. <i>Cancer Communications</i> , 2021, 41, 1387-1397.	3.7	6
139	Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer. <i>Cancer Research</i> , 2022, 82, 221-234.	0.4	6
140	AMP ed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy. <i>EMBO Molecular Medicine</i> , 2014, 6, 439-441.	3.3	5
141	Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness. <i>Urologic Clinics of North America</i> , 2021, 48, 339-347.	0.8	5
142	Hormone Whodunit: Clues for Solving the Case of Intratumor Androgen Production. <i>Clinical Cancer Research</i> , 2014, 20, 5343-5345.	3.2	3
143	Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle. <i>Molecular Pharmaceutics</i> , 2018, 15, 1778-1790.	2.3	3
144	Double Trouble: Concomitant RB1 and BRCA2 Depletion Evokes Aggressive Phenotypes. <i>Clinical Cancer Research</i> , 2020, 26, 1784-1786.	3.2	3

#	ARTICLE	IF	CITATIONS
145	Androgen Mediated Regulation of the G1-S Transition in Prostate Cancer. , 2002, , 91-110.		2
146	A tale of three PKCs. Cell Cycle, 2011, 10, 379-379.	1.3	1
147	IGF2 revs the steroidogenesis engine. Endocrine-Related Cancer, 2013, 20, C19-C21.	1.6	1
148	There and Back Again: The Middle Earth of DNA Repair. Molecular Cancer Research, 2016, 14, 895-897.	1.5	1
149	Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset. European Urology, 2019, 76, 338-339.	0.9	1
150	The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology. Journal of Personalized Medicine, 2021, 11, 330.	1.1	1
151	Androgen-mediated Control of the Cyclin D1-RB Axis: Implications for Prostate Cancer. Research and Perspectives in Endocrine Interactions, 2008, , 63-81.	0.2	1
152	Beyond the Cell Cycle: Implications of D-type Cyclin Deregulation in Prostate Cancer. , 2013, , 461-477.		0
153	Middlegame Theory, Cancer Style: A Message from the Editor-in-Chief. Molecular Cancer Research, 2013, 11, 3-4.	1.5	0
154	Fusing Transcriptomics to Progressive Prostate Cancer. American Journal of Pathology, 2014, 184, 2608-2610.	1.9	0
155	Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. Urology Case Reports, 2016, 9, 51-54.	0.1	0
156	Abstract IA9: Cross talk of the androgen receptor and DNA damage pathways: Molecular and translational prostate cancer relevance. Cancer Research, 2012, 72, IA9-IA9.	0.4	0
157	Splice Variants and Phosphorylated Isoforms of Cyclin D1 in Tumorigenesis. Current Cancer Research, 2018, , 91-109.	0.2	0